Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Macrogenics (NQ: MGNX )

3.240 +0.030 (+0.93%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Macrogenics

< Previous 1 2 3 4 5 6 7 8 9 Next >
Peeling Back The Layers: Exploring Macrogenics Through Analyst Insights
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
MacroGenics (MGNX) Q3 2024 Earnings Call Transcript
MGNX earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Macrogenics Earnings Preview
Via Benzinga
Macrogenics Stock: A Deep Dive Into Analyst Perspectives (9 Ratings)
Via Benzinga
Evaluating Macrogenics: Insights From 8 Financial Analysts
Via Benzinga
Expert Outlook: Macrogenics Through The Eyes Of 7 Analysts
Via Benzinga
Demystifying Macrogenics: Insights From 14 Analyst Reviews
Via Benzinga
After Reporting Five Patient Deaths, Data Committee Recommends MacroGenics Halt Prostate Cancer Trial
MacroGenics will discontinue vobra duo for remaining mCRPC participants after five deaths. New data to be presented at ESMO 2024 conference. 
Via Benzinga
Topics Death
Exposures Death
Match Group Layoffs 2024: What to Know About the Latest MTCH Job Cuts
Match Group layoffs are a hot topic on Wednesday as the dating website operator is preparing to reduce its headcount due to demand changes. 
Via InvestorPlace
Topics Workforce
Exposures Layoff
Why is Macrogenics (MGNX) Stock Down 28% Today?
Macrogenics stock is down on Wednesday after MGNX investors learned that the company is discontinuing a Phase 2 clinical trial. 
Via InvestorPlace
Pinterest Issues Weak Revenue Forecast, Joins Groupon, O-I Glass And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to dive into the biggest pre-market stock movers for Wednesday as we check out all of the hottest news happening this morning! 
Via InvestorPlace
Why AMD Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
DexCom, Zynex, Olin And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
3 Biotech Stocks That Could Be Millionaire-Makers: May Edition
Investors should take a close look at these biotech stocks as they position themselves to provide high returns. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Masters In Trading - Saturday, May 11
In this recap of the most recent trading session, I discuss earnings results and the market rally seen throughout the past week. 
Via Talk Markets
MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths'
Despite MacroGenics' clinical activity, unexpected adverse events raise concerns. Analysts adjust ratings and price targets. 
Via Benzinga
Crude Oil Down 1%; Sweetgreen Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
Stocks Pause On Dismal Consumer Confidence; Yields, Dollar Rise As Inflation Expectations Kick Higher, Bitcoin Sinks: What's Driving Markets Friday?
A worse-than-expected University of Michigan’s May consumer report halted stock gains on Friday, sparking worries about a potential decline in consumer health amid perceived rising price pressures. 
Via Benzinga
Topics Economy
Exposures Interest Rates
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Nasdaq Moves Lower; US Consumer Sentiment Falls In May
Via Benzinga
MacroGenics Shares Tumble After Reporting Adverse Events, Multiple Deaths In Cancer Drug Trial
Latest interim data from TAMARACK Phase 2 study by MacroGenics unveils insights into vobramitamab duocarmazine targeting B7-H3 in metastatic prostate cancer. Despite responses, notable safety concerns... 
Via Benzinga
Topics Death
Exposures Death
Dow Jumps Over 100 Points; DNOW Posts Downbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Progyny (PGNY) Stock Down 27% Today?
Progyny stock is down on Friday after the company posted a revenue miss for Q1 and disappointed PGNY investors with its guidance! 
Via InvestorPlace
Why Natera Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Is Macrogenics (MGNX) Stock Down 69% Today?
Macrogenics stock is down on Friday as MGNX investors react to clinical trial deaths and missed earnings for the first quarter of 2024. 
Via InvestorPlace
Topics Death
Exposures Death
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.